Baker SD - Search Results

1

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition.

Eisenmann ED, Fu Q, Muhowski EM, Jin Y, Uddin ME, Garrison DA, Weber RH, Woyach J, Byrd JC, Sparreboom A, Baker SD. Eisenmann ED, et al. Among authors: baker sd. Cancer Res Commun. 2021 Nov;1(2):79-89. doi: 10.1158/2767-9764.crc-21-0076. Epub 2021 Nov 9. Cancer Res Commun. 2021. PMID: 34950932 Free PMC article.

2

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Among authors: baker sd. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

3

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: baker sd. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

4

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: baker sd. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

5

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Baker SD, et al. Clin Cancer Res. 2004 Mar 15;10(6):1976-83. doi: 10.1158/1078-0432.ccr-0842-03. Clin Cancer Res. 2004. PMID: 15041715 Clinical Trial.

6

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.

Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A. Engels FK, et al. Among authors: baker sd. Clin Pharmacol Ther. 2004 May;75(5):448-54. doi: 10.1016/j.clpt.2004.01.001. Clin Pharmacol Ther. 2004. PMID: 15116057 Clinical Trial.

7

Determination of fraction unbound docetaxel using microequilibrium dialysis.

Acharya MR, Baker SD, Verweij J, Figg WD, Sparreboom A. Acharya MR, et al. Among authors: baker sd. Anal Biochem. 2004 Aug 1;331(1):192-4. doi: 10.1016/j.ab.2004.03.045. Anal Biochem. 2004. PMID: 15246014 No abstract available.

8

Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?

Sparreboom A, Baker SD, Verweij J. Sparreboom A, et al. Among authors: baker sd. J Clin Oncol. 2005 Nov 1;23(31):7765-7. doi: 10.1200/JCO.2005.03.7135. J Clin Oncol. 2005. PMID: 16258080 No abstract available.

9

Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.

van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. van Erp NP, et al. Among authors: baker sd. Clin Cancer Res. 2005 Nov 1;11(21):7800-6. doi: 10.1158/1078-0432.CCR-05-1288. Clin Cancer Res. 2005. PMID: 16278402

10

Clinical pharmacokinetics of docetaxel : recent developments.

Baker SD, Sparreboom A, Verweij J. Baker SD, et al. Clin Pharmacokinet. 2006;45(3):235-52. doi: 10.2165/00003088-200645030-00002. Clin Pharmacokinet. 2006. PMID: 16509758 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

268 results

Search Page